HZN-825 QD ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
51全身性強皮症1

51. 全身性強皮症


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04781543
(ClinicalTrials.gov)
April 1, 20211/3/2021A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic SclerosisA Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic Sclerosis;Sclerosis, SystemicDrug: HZN-825 BID;Drug: Placebo;Drug: HZN-825 QDHorizon Therapeutics Ireland DACNULLRecruiting18 Years75 YearsAll300Phase 2United States;Argentina;Austria;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom